About the Project
In particular will use very short burst microwave irradiation within the millisecond range and also short pulse ultrasound be used to stimulate p53 levels. The pre-existing technology to facilitate this approach has been made available with the industrial partnership of Dr William Henry, who is the Chief Scientific Officer with Teknolerge Ltd. Moreover, we have generated pilot data using the instrumentation that has led us to realise that microwaves in this regime [2.4 GHz for pulse lengths in the millisecond range and using milliwatt power ranges generated by the ’Pulsar technology’ ] can enhance activation of p53 in a controllable manner which complements other recent observations of electromagnetic (microwave) control of p53 . Importantly, we have also demonstrated the critical observation that the Pulsar technology developed by Teknolerge Ltd can activate p53 into a therapeutically useful level without itself generating DNA-damage. i.e. the technology appears to be non-invasive and non-gentoxic.
Here it should be noted that the p53 protein, for some time regarded as the ’guardian of the genome’ is pivotal in orchestrating the cellular defence against virus infection by coordinating the immune cell response and by preventing the virus to replicate in infected cells. Viral species usually target and inactivate p53 in order to exercise control of infected cells, subsequently disrupting an effective immune response. The coronavirus COVID19 is no exception. It inactivates p53, thus promoting fast virus replication and lowering the resistance of the immune system. Our strategy to deliberately [pre] activate p53 [in vulnerable patients], or reactively irradiate in those exposed to the virus, using the Pulsar technology may lead to prevention or reduction of [COVID-19] infection without iatrogenic factors, effectively enhancing immunological protection against Coronavirus.
Given suitable confirmation of Pulsar’s antiviral activity we would propose a clinical trial on Pulsar devices. This would involve the wearing of a device (externally) close to the top of the respiratory tract to deliver an immunological boost to these tissues. In the absence of a vaccine and in the uncertainty of drug efficacy, it is believed that any boost to the immune system is a valuable asset.
For informal enquiries about the project, contact Dr Paul Campbell (email@example.com)
For general enquiries about the University of Dundee, contact firstname.lastname@example.org
Applicants must have obtained, or expect to obtain, a first or 2.1 UK honours degree, or equivalent for degrees obtained outside the UK in a relevant discipline.
English language requirement: IELTS (Academic) score must be at least 6.5 (with not less than 5.5 in each of the four components). Other, equivalent qualifications will be accepted. Full details of the University’s English language requirements are available online: http://www.dundee.ac.uk/guides/english-language-requirements.
Step 1: Email Dr Paul Campbell (email@example.com) to (1) send a copy of your CV and (2) discuss your potential application and any practicalities (e.g. suitable start date).
Step 2: After discussion with Dr Campbell, formal applications can be made via UCAS Postgraduate:
Apply for the Doctor of Philosophy (PhD) degree in Physics: https://digital.ucas.com/coursedisplay/courses/07a14f7d-0d23-c83c-bae0-4dc4e2f7045f. Select the start date and study mode (full-time/part-time) agreed with the lead supervisor.
In the ‘provider questions’ section of the application form:
- Write the project title and ‘FindAPhD.com’ in the ‘if your application is in response to an advertisement’ box;
- Write the lead supervisor’s name and give brief details of your previous contact with them in the ‘previous contact with the University of Dundee’ box.
In the ‘personal statement’ section of the application form, outline your suitability for the project selected.
Interviews will be held as part of the recruitment process.
DNA double strand breaks induced by cavitational mechanical effects of ultrasound in cancer cells
Y Furusawa, Y Fujiwara, P Campbell, QL Zhao, R Ogawa, MA Hassan, Y Tabuchi, I Takasaki,
A Takahashi &,T Kondo
PloS One (2012) 7 (1) e29012 (2012)
Why not add a message here
Based on your current searches we recommend the following search filters.
Based on your current search criteria we thought you might be interested in these.